Myriad Genetics
MYGN
197 hedge funds and large institutions have $2.16B invested in Myriad Genetics in 2021 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 76 increasing their positions, 63 reducing their positions, and 37 closing their positions.
296% more call options, than puts
Call options by funds: $11M | Put options by funds: $2.77M
21% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 63
3.53% less ownership
Funds ownership: 101.55% → 98.03% (-3.5%)
8% less funds holding
Funds holding: 213 → 197 (-16)
15% less capital invested
Capital invested by funds: $2.55B → $2.16B (-$395M)
35% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 37
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$32.5M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$31.7M |
| 3 |
Millennium Management
New York
|
+$16.6M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$14.6M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$24.5M |
| 2 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$19.1M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$18.9M |
| 4 |
GCM
Glenview Capital Management
New York
|
-$16.1M |
| 5 |
Morgan Stanley
New York
|
-$11.7M |
MYGN Hedge Fund Activity: Q4 2021 in Review
197 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q4 2021, worth a combined $2.16B — down 15% from $2.55B a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of MYGN and 24 opened new positions — a net loss of 13 holders — while 63 trimmed existing stakes and 76 added.
The largest buyer was BlackRock, adding an estimated $32.5M. The largest seller was PFM Health Sciences, cutting an estimated $24.5M.
- 197 institutional investors held Myriad Genetics (MYGN) as of Q4 2021, down from 213 in Q3 2021.
- Funds reported $2.16B of Myriad Genetics stock for Q4 2021, down 15% quarter-over-quarter.
- 24 funds opened new Myriad Genetics positions in Q4 2021 and 37 closed out, a net change of -13 holders.
- The largest Myriad Genetics buyer in Q4 2021 was BlackRock, an estimated $32.5M added.
- The largest Myriad Genetics seller in Q4 2021 was PFM Health Sciences, an estimated $24.5M sold.
Based on aggregated 13F filings for Q4 2021.